By bnm Tel Aviv bureau US cybersecurity giant Palo Alto Networks announced its intent to acquire Israeli startup KOI for $400mn. This comes just a week after Palo Alto acquired another Israeli ...

CYR-064 is a patent-protected, intranasal formulation of a broad-spectrum phosphodiesterase (PDE) inhibitor with a patent-protected targeted delivery system designed to enhance olfactory neuron ...

The Koi deal comes one week after Palo Alto closed its acquisition of CyberArk to bolster its AI security portfolio.

CRN’s Security 100 list of the coolest network security companies includes vendors offering modern SASE platforms, next-gen ...

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

ADJUSTED EARNINGS PER SHARE: Analysts expect second-quarter adjusted earnings per share of 94 cents a share. Palo Alto Networks has said it expects adjusted earnings of 93 cents to 95 cents a share.

New research from Microsoft and Omdia reveals how fragmented tools, manual workflows, and alert overload are pushing SOCs to a breaking point.

Cyrano Therapeutics is savoring a phase 2 victory. With the Flavor study hitting its primary endpoint, the biotech is preparing to take its treatment for persistent smell loss into phase 3 in the ...

Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive ...

New REST API gives developers programmatic access to NIST FIPS 204 post-quantum document authentication — sign any ...

If Windows could not start the Windows Audio Endpoint Builder service on Local Computer, reinstall the audio driver, restart ...

We are grateful for the collaborative feedback from FDA on the Gemini program, which provides us a clear and expedient path forward for seeking approval of Gemini as a treatment for AKI,” said, James ...